Analyst Ratings for Fate Therapeutics
Portfolio Pulse from Benzinga Insights
Fate Therapeutics (NASDAQ:FATE) has received indifferent ratings from four analysts in the last quarter. The average 12-month price target for the company is $5.0, a decrease of 16.67% from the previous average price target of $6.00.
November 09, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fate Therapeutics has received indifferent ratings from analysts, with a decreased price target.
The indifferent ratings from analysts indicate uncertainty about the company's performance. The decrease in the price target suggests that analysts expect the stock price to decrease in the future, which could negatively impact investor sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100